Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 2/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | GRM8 | O00222 | 1/20 | 0.38 |
| ▸ | GRM6 | O15303 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3502798 | 1.00 | SLC1A5 (0.43) | SLC1A5NOS3NOS1NOS2IDO1 | |
| Glycine SCHEMBL8588130 | 0.96 | GLRA1 (0.42) | SLC1A5NOS3NOS1NOS2IDO1 | |
| SCHEMBL4752999 | 0.94 | SLC1A5 (0.40) | SLC1A5NOS3NOS1NOS2IDO1 | |
| SCHEMBL12500454 | 0.94 | SLC1A5 (0.40) | SLC1A5NOS3NOS1NOS2IDO1 | |
| Serine SCHEMBL7925097 | 0.92 | SLC1A5 (0.42) | SLC1A5NOS3NOS1NOS2IDO1 | |
| Alanine SCHEMBL5168125 | 0.92 | SLC7A5 (0.42) | SLC1A5NOS3NOS1NOS2IDO1 | |
| Aspartic Acid SCHEMBL15399013 | 0.90 | GRIK1 (0.38) | SLC1A5NOS3NOS1NOS2IDO1 | |
| Cysteine SCHEMBL2597897 | 0.90 | PTGS1 (0.59) | SLC1A5NOS3NOS1NOS2IDO1 | |
| Glycine SCHEMBL1548291 | 0.90 | SLC1A5 (0.38) | SLC1A5NOS3NOS1NOS2IDO1 | |
| SCHEMBL18152975 | 0.89 | SLC1A5 (0.37) | SLC1A5NOS3NOS1NOS2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649326-B2 | Functional, segregated, charged telodendrimers and nanocarriers and methods of making and using same | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-05-16 | — | — | US | claimed |
| CN-115128277-A | Group of biomarkers for evaluating PCOS (Primary biliary cirrhosis) oocyte quality, application and screening method | 深圳中山泌尿外科医院 | 2022-09-30 | — | — | CN | claimed |
| EP-3347053-B1 | FUNCTIONAL, SEGREGATED, CHARGED TELODENDRIMERS AND NANOCARRIERS AND METHODS OF MAKING AND USING SAME | THE RESEARCH FOUNDATION FOR STATE UNIV OF NEW YORK (US) | 2022-05-25 | — | — | EP | claimed |
| US-11219692-B2 | Porphyrin modified telodendrimers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-01-11 | — | — | US | claimed |
| US-10967003-B2 | Functional segregated telodendrimers and nanocarriers and methods of making and using same | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2021-04-06 | — | — | US | claimed |
| US-20200254012-A1 | FUNCTIONAL SEGREGATED TELODENDRIMERS AND NANOCARRIERS AND METHODS OF MAKING AND USING SAME | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2020-08-13 | — | — | US | claimed |
| EP-3035968-B1 | TELODENDRIMERS AND NANOCARRIERS AND METHODS OF USING SAME | UNIV NEW YORK STATE RES FOUND (US) | 2020-05-06 | — | — | EP | claimed |
| US-20200046841-A1 | PORPHYRIN MODIFIED TELODENDRIMERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-13 | — | — | US | claimed |
| US-10463694-B2 | Functional segregated telodendrimers and nanocarriers and methods of making and using same | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2019-11-05 | — | — | US | claimed |
| EP-3512569-A1 | IMPROVED HYBRID TELODENDRIMERS | The Regents of The University of California (US) | 2019-07-24 | — | — | EP | claimed |
| EP-2707419-A2 | REVERSIBLY CROSSLINKED MICELLE SYSTEMS | The Regents of the University of California (US) | 2014-03-19 | — | — | EP | claimed |
| WO-2012158622-A2 | REVERSIBLY CROSSLINKED MICELLE SYSTEMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-11-22 | — | — | WO | claimed |
| US-20090191610-A1 | Microorganisms With Increased Efficiency for Methionine Synthesis | EVONIK DEGUSSA GMBH (DE) | 2009-07-30 | — | — | US | claimed |
| EP-1931784-A2 | MICROORGANISMS WITH INCREASED EFFICIENCY FOR METHIONINE SYNTHESIS | BASF SE (DE) | 2008-06-18 | — | — | EP | claimed |
| WO-2007020295-A2 | MICROORGANISMS WITH INCREASED EFFICIENCY FOR METHIONINE SYNTHESIS | BASF AG (DE) | 2007-02-22 | — | — | WO | claimed |
| WO-2002086153-A1 | DETERMINING RESISTANCE TO A $G(b)-LACTAM-CONTAINING ANTIBIOTIC BY COMPARING THE RATIO OF TWO $G(b)-LACTAMASE GENES | DIATECH PTY LTD (AU) | 2002-10-31 | — | — | WO | claimed |
| WO-2002053526-A1 | NEW COMPOUNDS FOR USE AS INTERMEDIATES IN LINEAR BLOCK POLYMER AND NEW LINEAR BLOCK POLYMER | ARTIMPLANT AB (SE) | 2002-07-11 | — | — | WO | claimed |
| WO-2002053616-A1 | NEW LINEAR BLOCK POLYMER | ARTIMPLANT AB (SE) | 2002-07-11 | — | — | WO | claimed |
| EP-0332225-B1 | ANTIBODY TO POLYPEPTIDES COMPLEMENTARY TO PEPTIDES OR PROTEINS HAVING AN AMINO ACID SEQUENCE OR NUCLEOTIDE CODING SEQUENCE AT LEAST PARTIALLY KNOWN AND METHODS OF DESIGN THEREFOR | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1993-04-21 | — | — | EP | claimed |
| US-4360458-A | PEPTIDE ANTIBIOTICS, ANTIBIOTIC BBM-928 | BRISTOL-MYERS COMPANY (US) | 1982-11-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200254012-A1 | FUNCTIONAL SEGREGATED TELODENDRIMERS AND NANOCARRIERS AND METHODS OF MAKING AND USING SAME | TTI2, TELO2, BICRA | SLC1A5 3340/4885NOS3 2719/4885NOS1 3439/4885 |
| US-20200046841-A1 | PORPHYRIN MODIFIED TELODENDRIMERS | CETP, NR1H4, ABCB4 | SLC1A5 884/4885NOS3 4301/4885NOS1 4123/4885 |
| US-10967003-B2 | Functional segregated telodendrimers and nanocarriers and methods of making and using same | TTI2, TELO2, BICRA | SLC1A5 3340/4885NOS3 2719/4885NOS1 3439/4885 |
| US-10463694-B2 | Functional segregated telodendrimers and nanocarriers and methods of making and using same | TTI2, TELO2, BICRA | SLC1A5 3340/4885NOS3 2719/4885NOS1 3439/4885 |
| US-11649326-B2 | Functional, segregated, charged telodendrimers and nanocarriers and methods of making and using same | TSPO, TBCA, TTI2 | SLC1A5 299/4885NOS3 4192/4885NOS1 4083/4885 |
| US-11219692-B2 | Porphyrin modified telodendrimers | CETP, NR1H4, ABCB4 | SLC1A5 884/4885NOS3 4301/4885NOS1 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.